Comparative Real‐World Effectiveness of Immunomodulatory Therapies for Prevention of Uveitis Relapse in Behçet Disease
Arthritis & Rheumatology · 2026-02 · 78 (2) · 438-448
DOI: 10.1002/art.43382 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 09.12.2025. Verfasst von Zhenyu Zhong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Ophthalmology Medical Center, Chongqing Key Laboratory for the Prevention and Treatment of Major Blinding Eye Diseases, The First Affiliated Hospital…. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Qiande Scientific Talents, Chongqing Science and Technology Bureau Mountaineering Project, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Objective
To evaluate comparative effectiveness of cyclosporine, interferon alfa‐2a, and adalimumab for the prevention of uveitis relapse in Behçet disease in real‐world settings.
Methods
We emulated a target trial involving adult patients with Behçet disease uveitis who initiated cyclosporine, interferon alfa‐2a, or adalimumab between April 10, 2008, and August 1, 2024, and were observed up until September 10, 2024. We applied overlap weighting to balance patient characteristics across treatment groups and emulate randomization at baseline. The primary outcome was the annualized relapse rate of uveitis during treatment with study therapy.
Results
The cohort comprised 716 cyclosporine users, 193 interferon alfa‐2a users, and 103 adalimumab users. The estimated mean annualized relapse rate of uveitis was 0.95 (95% confidence interval [CI] 0.82–1.10) with cyclosporine, 0.52 (95% CI 0.40–0.69) with interferon alfa‐2a, and 0.28 (95% CI 0.19–0.43) with adalimumab. Patients treated with cyclosporine experienced more relapses than those treated with adalimumab (incidence rate ratio [IRR] 3.36 [95% CI 2.23–5.05]; mean difference 0.66 [95% CI 0.48–0.85]; P < 0.001) or interferon alfa‐2a (IRR 1.81 [95% CI 1.37–2.4]; mean difference 0.42 [95% CI 0.22–0.62]; P < 0.001). The relapse rate was higher with interferon alfa‐2a than with adalimumab (IRR 1.86 [95% CI 1.16–2.97]; mean difference 0.24 [95% CI 0.05–0.43]; P = 0.011).
Conclusion
In Behçet disease, interferon alfa‐2a was associated with a reduction in uveitis relapse compared with cyclosporine, whereas adalimumab demonstrated a stronger association with reduced relapse than interferon alfa‐2a. image
Autor:innen und Institutionen
- Ophthalmology Medical Center, Chongqing Key Laboratory for the Prevention and Treatment of Major Blinding Eye Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- The First Affiliated Hospital of Zhengzhou University, Henan Province Eye Hospital, Henan International Joint Research Laboratory for Ocular Immunology and Retinal Injury Repair, Zhengzhou, China.
ORCID-Profile: Zhenyu Zhong, Peizeng Yang
Förderung
- Qiande Scientific Talents
- Chongqing Science and Technology Bureau Mountaineering Project
- China Postdoctoral Science Foundation
- Chongqing Medical Scientific Research Project: Joint Project of Chongqing Health Commission and Science and Technology Bureau
- National Natural Science Foundation of China
- National Natural Science Foundation Key Program
Zitieren
APA
Zhong, Z., Wang, J., Xia, L., Jing, S., Lai, Y., Cai, T., & Yang, P. (2026). Comparative Real‐World Effectiveness of Immunomodulatory Therapies for Prevention of Uveitis Relapse in Behçet Disease. Arthritis & Rheumatology, 78(2), 438-448. https://doi.org/10.1002/art.43382
Vancouver
Zhong Z, Wang J, Xia L, Jing S, Lai Y, Cai T, et al. Comparative Real‐World Effectiveness of Immunomodulatory Therapies for Prevention of Uveitis Relapse in Behçet Disease. Arthritis & Rheumatology. 2026;78(2):438-448. doi:10.1002/art.43382
BibTeX
@article{Zhong2026,
author = {Zhong, Zhenyu and Wang, Jiayi and Xia, Lan and Jing, Shixiang and Lai, Yujie and Cai, Tao and Yang, Peizeng},
title = {Comparative Real‐World Effectiveness of Immunomodulatory Therapies for Prevention of Uveitis Relapse in Behçet Disease},
journal = {Arthritis & Rheumatology},
year = {2026},
volume = {78},
number = {2},
pages = {438--448},
doi = {10.1002/art.43382}
}
EUVIMED